O-Glycosylation occurs in recombinant proteins produced by CHO cells, but this phenomenon has not been studied extensively. Here, we report that rituximab is an O-linked N-acetyl-glucosaminylated (O-GlcNAcylated) protein and the production of rituximab is increased by thiamet G, an inhibitor of O-GlcNAcase. The production of rituximab doubled with OGA inhibition and decreased with O-GlcNAc transferase inhibition. O-GlcNAc-specific antibody and metabolic labelling with azidO-GlcNAc confirmed the increased O-GlcNAcylation with thiamet G. Protein mass analysis revealed that serine 7, 12, and 14 of the rituximab light chain were O-GlcNAcylated. S12A mutation of the light chain decreased rituximab stability and failed to increase the production with thiamet G without any significant changes of mRNA level. Cytotoxicity and thermal stability assays confirmed that there were no differences in the biological and physical properties of rituximab produced by thiamet G treatment. Therefore, thiamet G treatment improves the production of rituximab without significantly altering its function.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Antibody-dependent cell cytotoxicity
Chinese Hamster Ovary cell line
Tedder TF, Klejman G, Disteche CM, Adler DA, Schlossman SF, Saito H (1988) Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. J Immunol 141:4388–4394 (Baltimore, Md.: 1950)
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50
Audagnotto M, Dal Peraro M (2017) Protein post-translational modifications: in silico prediction tools and molecular modeling. Comput Struct Biotechnol J 15:307–319
Van den Steen P, Rudd PM, Dwek RA, Opdenakker G (1998) Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 33:151–208
Subedi GP, Barb AW (2015) The structural role of antibody N-Glycosylation in receptor interactions. Structure 23:1573–1583 (London, England: 1993)
Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umana P (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402
Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112:2390–2399
Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A (2014) Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. mAbs 6:422–436
Ishino T, Wang M, Mosyak L, Tam A, Duan W, Svenson K, Joyce A, O'Hara DM, Lin L, Somers WS, Kriz R (2013) Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem 288:16529–16537
Gu J, Lei Y, Huang Y, Zhao Y, Li J, Huang T, Zhang J, Wang J, Deng X, Chen Z, Korteweg C, Deng R, Yan M, Xu Q, Dong S, Cai M, Luo L, Huang G, Wang Y, Li Q, Lin C, Su M, Yang C, Zhuang Z (2015) Fab fragment glycosylated IgG may play a central role in placental immune evasion. Hum Reprod (Oxford, England) 30:380–391
Wopereis S, Lefeber DJ, Morava E, Wevers RA (2006) Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin Chem 52:574–600
Hanisch FG (2001) O-glycosylation of the mucin type. Biol Chem 382:143–149
Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA (2012) Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22:736–756
Yang X, Qian K (2017) Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol 18:452–465
Hart GW, Housley MP, Slawson C (2007) Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446:1017–1022
Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P, Hart GW (2008) O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 283:16283–16292
Han I, Kudlow JE (1997) Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 17:2550–2558
Zhu Y, Liu TW, Cecioni S, Eskandari R, Zandberg WF, Vocadlo DJ (2015) O-GlcNAc occurs cotranslationally to stabilize nascent polypeptide chains. Nat Chem Biol 11:319–325
Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE (2003) O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115:715–725
Wang J, Torii M, Liu H, Hart GW, Hu ZZ (2011) dbOGAP—an integrated bioinformatics resource for protein O-GlcNAcylation. BMC Bioinform 12:91
Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ (2008) A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4:483–490
Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, Duveau DY, Tan ZW, Thomas CJ, Walker S (2015) A small molecule that inhibits OGT activity in cells. ACS Chem Biol 10:1392–1397
Lee JW, Heo W, Lee J, Jin N, Yoon SM, Park KY, Kim EY, Kim WT, Kim JY (2018) The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells. PLoS ONE 13:e0191075
Laughlin ST, Bertozzi CR (2007) Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. Nat Protoc 2:2930–2944
Vocadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR (2003) A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci USA 100:9116–9121
Boyd PN, Lines AC, Patel AK (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32:1311–1318
Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466–3473
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 12:2031–2042
Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 37:697–706
Sola RJ, Griebenow K (2009) Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98:1223–1245
Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem (Clifton, N.J.) 80:825–858
Zachara NE (2009) Detecting the "O-GlcNAc-ome"; detection, purification, and analysis of O-GlcNAc modified proteins. Methods Mol Biol 534:251–279
Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, Cho JW (2006) Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 8:1074–1083
Seo HG, Kim HB, Kang MJ, Ryum JH, Yi EC, Cho JW (2016) Identification of the nuclear localisation signal of O-GlcNAc transferase and its nuclear import regulation. Sci Rep 6:34614
Ji S, Park SY, Roth J, Kim HS, Cho JW (2012) O-GlcNAc modification of PPARgamma reduces its transcriptional activity. Biochem Biophys Res Commun 417:1158–1163
Li B, Kohler JJ (2014) Glycosylation of the nuclear pore. Traffic (Copenhagen, Denmark) 15:347–361
Zhu Y, Liu TW, Madden Z, Yuzwa SA, Murray K, Cecioni S, Zachara N, Vocadlo DJ (2016) Post-translational O-GlcNAcylation is essential for nuclear pore integrity and maintenance of the pore selectivity filter. J Mol Cell Biol 8:2–16
Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE (1999) An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J Biol Chem 274:15194–15202
Eijkelenboom A, Burgering BM (2013) FOXOs: signalling integrators for homeostasis maintenance. Nature reviews. Mol Cell Biol 14:83–97
Fardini Y, Perez-Cervera Y, Camoin L, Pagesy P, Lefebvre T, Issad T (2015) Regulatory O-GlcNAcylation sites on FoxO1 are yet to be identified. Biochem Biophys Res Commun 462:151–158
Hastings NB, Wang X, Song L, Butts BD, Grotz D, Hargreaves R, Fred Hess J, Hong K-LK, Huang CR-R, Hyde L, Laverty M, Lee J, Levitan D, Lu SX, Maguire M, Mahadomrongkul V, McEachern EJ, Ouyang X, Rosahl TW, Selnick H, Stanton M, Terracina G, Vocadlo DJ, Wang G, Duffy JL, Parker EM, Zhang L (2017) Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener 12:39
Zeidan Q, Wang Z, De Maio A, Hart GW (2010) O-GlcNAc cycling enzymes associate with the translational machinery and modify core ribosomal proteins. Mol Biol Cell 21:1922–1936
Fisi V, Miseta A, Nagy T (2017) The role of stress-induced O-GlcNAc protein modification in the regulation of membrane transport. Oxid Med Cell longev 2017:15
Lagerlof O, Hart GW, Huganir RL (2017) O-GlcNAc transferase regulates excitatory synapse maturity. Proc Natl Acad Sci USA 114:1684–1689
Sakaidani Y, Ichiyanagi N, Saito C, Nomura T, Ito M, Nishio Y, Nadano D, Matsuda T, Furukawa K, Okajima T (2012) O-linked-N-acetylglucosamine modification of mammalian Notch receptors by an atypical O-GlcNAc transferase Eogt1. Biochem Biophys Res Commun 419:14–19
Netsirisawan P, Chokchaichamnankit D, Srisomsap C, Svasti J, Champattanachai V (2015) Proteomic analysis reveals aberrant O-GlcNAcylation of extracellular proteins from breast cancer cell secretion. Cancer Genomics Proteomics 12:201–209
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29:310–312
Mellahi K, Brochu D, Gilbert M, Perrier M, Ansorge S, Durocher Y, Henry O (2019) Process intensification for the production of rituximab by an inducible CHO cell line. Bioprocess Biosyst Eng 42:711–725
Zhang P, Woen S, Wang T, Liau B, Zhao S, Chen C, Yang Y, Song Z, Wormald MR, Yu C, Rudd PM (2016) Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today 21:740–765
Yang Z, Halim A, Narimatsu Y, Jitendra Joshi H, Steentoft C, Schjoldager KT, Alder Schulz M, Sealover NR, Kayser KJ, Paul Bennett E, Levery SB, Vakhrushev SY, Clausen H (2014) The GalNAc-type O-Glycoproteome of CHO cells characterized by the SimpleCell strategy. Mol Cell proteomics 13:3224–3235
Wang Y, Ju T, Ding X, Xia B, Wang W, Xia L, He M, Cummings RD (2010) Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci USA 107:9228–9233
Yang YR, Song M, Lee H, Jeon Y, Choi EJ, Jang HJ, Moon HY, Byun HY, Kim EK, Kim DH, Lee MN, Koh A, Ghim J, Choi JH, Lee-Kwon W, Kim KT, Ryu SH, Suh PG (2012) O-GlcNAcase is essential for embryonic development and maintenance of genomic stability. Aging Cell 11:439–448
This work was supported by grants from the National Research Foundation of Korea, Project No. NFR-2018R1A2B4010319 and a faculty research grant from Yonsei University College of Medicine (6-2018-0070) to J. Y Kim.
Conflict of interest
No potential conflict of interest reported by the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kim, HY., Park, M., Kang, C. et al. O-GlcNAcylation of light chain serine 12 mediates rituximab production doubled by thiamet G. Bioprocess Biosyst Eng 43, 863–875 (2020). https://doi.org/10.1007/s00449-020-02282-z
- Production yield
- Thiamet G
- Thermal stability